Story perspectives

AstraZeneca Unveils $4.5B Plant Amid Drug Price Deals

10/10/2025

Summary

Story summary

AstraZeneca announced the groundbreaking of a $4.5 billion manufacturing plant in Virginia, its largest worldwide, to support increased domestic drug production.
The facility will create 600 skilled jobs and 3,000 construction jobs as part of a broader $50 billion plan to expand U.S. research and manufacturing by 2030.
Pfizer reached a deal with the Trump administration to cap drug prices and avoid new tariffs, pledging $70 billion in U.S. investments and offering discounts on select treatments.
Both companies' actions raise questions about the political motivations behind these industry changes.

History

Historical Context

The 1965 U.S. Drug Amendments significantly expanded the FDA's authority over drug approvals, prompting pharmaceutical companies like AstraZeneca and Pfizer to invest in domestic production. AstraZeneca's $4.5 billion plant in Virginia created 600 jobs, reflecting a broader trend towards local manufacturing aimed at ensuring drug affordability and availability amid ongoing political and economic pressures.

1 of 2

Story summary

AstraZeneca announced the groundbreaking of a $4.5 billion manufacturing plant in Virginia, its largest worldwide, to support increased domestic drug production.
The facility will create 600 skilled jobs and 3,000 construction jobs as part of a broader $50 billion plan to expand U.S. research and manufacturing by 2030.
Pfizer reached a deal with the Trump administration to cap drug prices and avoid new tariffs, pledging $70 billion in U.S. investments and offering discounts on select treatments.
Both companies' actions raise questions about the political motivations behind these industry changes.

1 / 2